Watch stories about real HAEGARDA patients living the difference
THE RIGHT THERAPY FOR YOU MATTERS
IN A CLINICAL STUDY, HAEGARDA reduced attacks by 95%*
HAEGARDA helps patients with HAE live the difference.
With HAEGARDA, HAE
attacks were reduced by
As a preventive therapy, HAEGARDA can effectively reduce the number of HAE attacks you experience.
*In the clinical trial, the median reduction in number of attacks in people receiving HAEGARDA 60 IU/kg vs. placebo.
Rescue medication use
was reduced by
You should always have HAE rescue medication available at all times in case of a breakthrough attack.
†In the clinical trial, the median reduction in rescue medication use in people receiving HAEGARDA 60 IU/kg vs. placebo.
Main Study:
- 90 adult and adolescent patients with HAE type I or II, who had HAE symptoms
- Patients self-administered HAEGARDA in one 16-week treatment period and placebo in the other 16-week treatment period
- Neither doctors nor patients knew which medicine (HAEGARDA or placebo) they were taking at any time during the study
- Study goals included seeing how well HAEGARDA reduced HAE attack rates compared to placebo
Extension Study:
- 120 adult and pediatric patients with HAE type I or II, who had HAE symptoms
- Patients self-administered HAEGARDA for an average of 1.4 years, some for more than 2 years
- Doctors and patients knew which medicine (HAEGARDA) they were taking during the study
- Study goals included seeing how well HAEGARDA reduced HAE attack rates during the study, and long-term safety
The root cause of HAE is missing or nonworking C1 esterase inhibitor (C1-INH), a key protein in your body that controls swelling
HAE attacks
can occur when your levels of working C1-INH are too low or not functional (nonworking)
HAEGARDA adds
working C1-INH to your body
HAEGARDA brings your working C1-INH levels back up
and closer to normal, preventing an HAE attack